Nuvalent Announced Cancer Discovery Publication Highlighting Design, Preclinical Activity, and Early Clinical Data of ALK-Selective Inhibitor NVL-655
Nuvalent Announced Cancer Discovery Publication Highlighting Design, Preclinical Activity, and Early Clinical Data of ALK-Selective Inhibitor NVL-655
- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-655 and details Nuvalent's approach to rationally targeting ALK. NVL-655 is currently being studied in the ongoing ALKOVE-1 Phase 1/2 clinical trial for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.
- Nuvalent, Inc. (納斯達克:NUVL)是一家臨床階段生物製藥公司，專注於爲癌症中已經證實的激酶靶點精準創建療法。今天，該公司宣佈在《抗癌醫藥發現》雜誌上發表了一篇手稿，描述了NVL-655的設計和表徵，並詳細介紹了Nuvalent公司有針對性地瞄準ALk的方法。 NVL-655目前正在進行ALKOVE-1階段1/2臨床試驗，用於治療愛文思控股-陽性非小細胞肺癌（NSCLC）和其他實體腫瘤。
譯文內容由第三人軟體翻譯。